China
Africa
Explore chapters and articles related to this topic
Solar Urticaria/Sun Allergy
Published in Charles Theisler, Adjuvant Medical Care, 2023
Solar urticaria, also known as sun allergy, is a rare allergy to sunlight that causes a red rash to form on skin that is exposed to the sun. Itchy, reddish spots or welts usually appear within minutes of sun exposure.1 The reaction may subside in a few minutes or last an hour or more. If large areas of the body are affected, the loss of fluid into the skin may result in light-headedness, headache, nausea, and vomiting. The mean age of onset is 35 years, but it has occurred in infants and individuals up through the age of 70.1
Urticaria and Angioedema
Published in Pudupakkam K Vedanthan, Harold S Nelson, Shripad N Agashe, PA Mahesh, Rohit Katial, Textbook of Allergy for the Clinician, 2021
Jenny M Stitt, Stephen C Dreskin
Solar urticaria is a rare disorder that occurs after minutes of exposure to sunlight. Pruritus, erythema and swelling occur and are confined to UV light-exposed areas. With exposure of a large body surface area, systemic symptoms such as bronchoconstriction, hypotension and even death may occur.
Solar Urticaria
Published in Henry W. Lim, Nicholas A. Soter, Clinical Photomedicine, 2018
Solar urticaria is a rare photosensitivity disease. In the past 15 years, the author has seen approximately 30 patients. Ive et al. described 17 patients with solar urticaria over a period of 5 years (1). Patients with solar urticaria have been reported throughout the world. Although it occurs equally in both sexes in the author’s own experience, a slight preponderance in women has been described in the literature. The age of onset ranges from the first to the eighth decades. There has been only one instance of siblings with solar urticaria (2).
Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence
Published in Journal of Dermatological Treatment, 2018
Jesper Grønlund Holm, Ilya Ivyanskiy, Simon Francis Thomsen
Intravenous immunoglobulin G (IVIG) is a polyvalent antibody product comprising mainly IgG obtained from pooled serum of healthy donors. The mode of action is not entirely understood. Possibly, it blocks the Fc-portion of IgG in reticuloendothelial cells and directly inhibits B-cell and/or T-cell function; inhibits complement-mediated damage; modulates cytokines production; and neutralizes circulating autoantibodies by anti-idiotypic antibodies contained in IVIG. Its use in the treatment of chronic urticaria has been extensively described. We identified 16 studies including 89 patients. However, 14/16 studies include less than 10 patients and six are single case reports. None of the studies were randomized or included control groups which inhibit the evidential value. The most recent study by Aubin et al (39), published in 2014, treated nine patients suffering from solar urticaria (SU), using photograph testing to evaluate treatment response. Despite high number of adverse events, which all resolved, 7/9 patients showed improvement from treatment, of which two had complete response. Pereira et al (40) treated 29 patients suffering from autoimmune urticaria, showing full remission of symptoms in 19/29 patients. Conversely, three patients dropped out due to lack of effect or severe adverse effects. The total number of complete remissions overall was 40/88 (45.5%). This somehow makes up for the relatively high number of reported adverse effects in the immunoglobulin studies compared to other treatments (Table 2).
Redefining electrosensitivity: A new literature-supported model
Published in Electromagnetic Biology and Medicine, 2021
In this paper, we present a model of EHS and other RFR-related disorders/illnesses in a whole-of-health context recognising that everyone is electrosensitive. Consequently, and notwithstanding von Pirquet’s definition, the term electroHYPERsensitive is only truly relevant to the extreme condition, near the periphery of the upper left side of figure 1.3Note, it is possible to be hyper-sensitive/allergic to the sun. This condition is called solar urticaria.
Emerging treatments for chronic urticaria
Published in Expert Opinion on Investigational Drugs, 2022
Moreover, omalizumab was also shown to be effective in CINDU [24–26] including cholinergic urticaria [27], cold urticaria [28,29], heat urticaria [30], solar urticaria [31], symptomatic dermographism [32,33], as well as delayed pressure urticaria [34], although data are limited to case reports, case series, or small RCTs. Within an observational study of 80 patients with CINDU, solar urticaria demonstrated best, and symptomatic dermographism poorest response [26].